Nothing Special   »   [go: up one dir, main page]

PE20090110A1 - Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 - Google Patents

Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90

Info

Publication number
PE20090110A1
PE20090110A1 PE2008000409A PE2008000409A PE20090110A1 PE 20090110 A1 PE20090110 A1 PE 20090110A1 PE 2008000409 A PE2008000409 A PE 2008000409A PE 2008000409 A PE2008000409 A PE 2008000409A PE 20090110 A1 PE20090110 A1 PE 20090110A1
Authority
PE
Peru
Prior art keywords
alkyl
hsp90
amine
diona
halogen
Prior art date
Application number
PE2008000409A
Other languages
English (en)
Inventor
Nobuo Shimma
Takuo Tsukuda
Hiroshi Koyano
Atsushi Suda
Tadakatsu Hayase
Kihito Hada
Ken-Ichi Kawasaki
Susumu Komiyama
Naomi Ono
Toshikazu Yamazaki
Ryoichi Saitoh
Masami Kohchi
Kiyoshi Hasegawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20090110A1 publication Critical patent/PE20090110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN DERIVADO DE AMINA DE FORMULA (1), DONDE X ES CH O N; R1 ES H, HALOGENO, CIANO, ENTRE OTROS; R2 ES ALQUILO C1-C6, ALQUENILO C2-C6, H, ENTRE OTROS; R3 ES H, HALOGENO, CIANO, ENTRE OTROS; R4 ES ALQUILO C1-C6, ALQUENILO C2-C6, H, HALOGENO, ENTRE OTROS; R5, R6 Y R7 SON ALQUILENO C1-C6, ALQUENILENO C2-C6, CICLOALQUILENO C3-C10, ENTRE OTROS; L1, L2 Y L3 SON UN ENLACE SIMPLE, NR8, CONR8, O, ENTRE OTROS; R8 ES H, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: 4-AMINO-20,22-DIMETIL-7-TIA-3,5,11,17-TETRAAZACICLO[17.3.1.12,6]TETRACOSA-1(22),2(24),3,5,19(23),20-HEXAENO-10,18-DIONA, 4-AMINO-18,20-DIMETIL-7-TIA-3,5,11,15-TETRAAZATRICICLO[15.3.1.12,6]DOCOSA-1(20),2(22),3,5,17(21),18-HEXANO-10,16-DIONA, 4-AMINO-15,18,20-TRIMETIL-7-TIA-3,5,11,15-TETRAAZATRICICLO[15.3.1.12,6]DOCOSA-1(20),2(22),3,5,17(21),18-HEXANO-10,16-DIONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE LA PROTEINA DE SHOCK TERMICO 90 (HSP90) Y SON UTILES EN EL TRATAMIENTO ANTICANCEROSO U ANTITUMORAL
PE2008000409A 2007-03-01 2008-02-29 Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 PE20090110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007052072 2007-03-01

Publications (1)

Publication Number Publication Date
PE20090110A1 true PE20090110A1 (es) 2009-04-04

Family

ID=39721348

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000409A PE20090110A1 (es) 2007-03-01 2008-02-29 Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90

Country Status (18)

Country Link
US (1) US8362236B2 (es)
EP (1) EP2119718B1 (es)
JP (1) JP5235859B2 (es)
KR (1) KR20090125155A (es)
CN (1) CN101675059A (es)
AR (1) AR065583A1 (es)
AT (1) ATE553107T1 (es)
AU (1) AU2008220009A1 (es)
BR (1) BRPI0808524A2 (es)
CA (1) CA2679126A1 (es)
CL (1) CL2008000629A1 (es)
IL (1) IL200009A0 (es)
MX (1) MX2009008756A (es)
PE (1) PE20090110A1 (es)
RU (1) RU2009136343A (es)
TW (1) TW200904435A (es)
WO (1) WO2008105526A1 (es)
ZA (1) ZA200905116B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
PE20090110A1 (es) 2007-03-01 2009-04-04 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
SG11201405628YA (en) * 2012-03-17 2014-10-30 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
EP2970334B1 (en) * 2013-03-15 2018-05-23 Biogen MA Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
PL3053578T3 (pl) 2013-09-30 2021-06-14 Taiho Pharmaceutical Co., Ltd. Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
US11807664B2 (en) 2017-05-12 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound
CN115124550B (zh) * 2020-10-26 2024-04-02 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170780A (ja) 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinabenzoguanidoruino seiho
JPS60208968A (ja) 1984-03-07 1985-10-21 イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー 除草剤性フルオロエトキシピリミジン類及びトリアジン類
AU585761B2 (en) 1984-03-07 1989-06-22 E.I. Du Pont De Nemours And Company Herbicidal fluoroethoxy triazines
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO1998019648A2 (en) 1996-11-01 1998-05-14 Warner-Lambert Company N-oxy-naphthalimides as antibacterial agents
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
NZ520241A (en) 2000-02-25 2004-05-28 F Adenosine receptor modulators
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
JP2004505044A (ja) 2000-07-28 2004-02-19 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 細胞増殖性障害およびウイルス感染の治療方法
EP1337275A4 (en) 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
CN1501928A (zh) 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US7291616B2 (en) 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
DE60222804T2 (de) 2001-12-21 2008-07-03 Vernalis (Cambridge) Ltd., Abington 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
NZ546044A (en) 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
JP2005225787A (ja) * 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
JP2008540626A (ja) 2005-05-19 2008-11-20 アステックス、セラピューティックス、リミテッド 医薬化合物
KR101499594B1 (ko) 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체
AR061185A1 (es) * 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
PE20090110A1 (es) 2007-03-01 2009-04-04 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
JP2009067729A (ja) 2007-09-14 2009-04-02 Kyowa Hakko Kirin Co Ltd Ｈｓｐ９０ファミリー蛋白質阻害剤
MX2010008269A (es) 2008-02-01 2011-02-21 Takeda Pharmaceutical Inhibidores de hsp90.

Also Published As

Publication number Publication date
ATE553107T1 (de) 2012-04-15
US8362236B2 (en) 2013-01-29
IL200009A0 (en) 2010-04-15
EP2119718A1 (en) 2009-11-18
AU2008220009A1 (en) 2008-09-04
BRPI0808524A2 (pt) 2014-11-11
CA2679126A1 (en) 2008-09-04
ZA200905116B (en) 2010-07-28
CN101675059A (zh) 2010-03-17
RU2009136343A (ru) 2011-04-10
WO2008105526A1 (ja) 2008-09-04
AR065583A1 (es) 2009-06-17
JPWO2008105526A1 (ja) 2010-06-03
TW200904435A (en) 2009-02-01
CL2008000629A1 (es) 2008-08-29
MX2009008756A (es) 2009-08-27
US20100056510A1 (en) 2010-03-04
EP2119718B1 (en) 2012-04-11
JP5235859B2 (ja) 2013-07-10
KR20090125155A (ko) 2009-12-03
EP2119718A4 (en) 2010-12-15

Similar Documents

Publication Publication Date Title
PE20090110A1 (es) Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20080695A1 (es) Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PE20081447A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
PE20090511A1 (es) Imidazopiridinonas
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20081887A1 (es) Nuevo compuesto de adenina
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
PE20070181A1 (es) DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA
UY28150A1 (es) Agentes terapeuticos
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina

Legal Events

Date Code Title Description
FX Voluntary withdrawal